GlaxoSmithKline PLC’s anti-B-cell maturation antigen (BCMA) therapy has improved outcomes in a pivotal multiple myeloma trial, setting the company up to file for approval by the end of the year.
The asset, belantamab mafodotin, is an anti-BCMA antibody-drug conjugate (ADC) that uses a linker technology licensed from Seattle Genetics Inc.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?